Loading...

Entera Bio

Nasdaq:ENTX
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ENTX
Nasdaq
$44M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Entera Bio has significant price volatility in the past 3 months.
ENTX Share Price and Events
7 Day Returns
-5.2%
NasdaqCM:ENTX
1%
US Biotechs
0.2%
US Market
1 Year Returns
-
NasdaqCM:ENTX
-4.6%
US Biotechs
2.9%
US Market
ENTX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Entera Bio (ENTX) -5.2% -10.5% -15.9% - - -
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • No trading data on ENTX.
  • No trading data on ENTX.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Entera Bio's competitors could be found in our database.

ENTX Value

 Is Entera Bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Entera Bio. This is due to cash flow or dividend data being unavailable. The share price is $3.82.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Entera Bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Entera Bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:ENTX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.30
NasdaqCM:ENTX Share Price ** NasdaqCM (2019-05-22) in USD $3.82
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Entera Bio.

NasdaqCM:ENTX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ENTX Share Price ÷ EPS (both in USD)

= 3.82 ÷ -1.30

-2.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Entera Bio is loss making, we can't compare its value to the US Biotechs industry average.
  • Entera Bio is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Entera Bio's expected growth come at a high price?
Raw Data
NasdaqCM:ENTX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.95x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
42.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Entera Bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Entera Bio's assets?
Raw Data
NasdaqCM:ENTX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.88
NasdaqCM:ENTX Share Price * NasdaqCM (2019-05-22) in USD $3.82
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqCM:ENTX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ENTX Share Price ÷ Book Value per Share (both in USD)

= 3.82 ÷ 0.88

4.33x

* Primary Listing of Entera Bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Entera Bio is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Entera Bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Entera Bio has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ENTX Future Performance

 How is Entera Bio expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
42.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Entera Bio expected to grow at an attractive rate?
  • Entera Bio's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Entera Bio's earnings growth is expected to exceed the United States of America market average.
  • Entera Bio's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:ENTX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:ENTX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 42.4%
NasdaqCM:ENTX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 81.2%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:ENTX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:ENTX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 83 48 1
2022-12-31 10 -11 1
2021-12-31 0 -21 1
2020-12-31 0 -15 1
2019-12-31 0 -13 1
NasdaqCM:ENTX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -10 -10
2018-09-30 -9 -11
2018-06-30 -8 -10
2018-03-31 -6 -11
2017-12-31 -5 -11
2017-09-30 -4 -8
2017-06-30 -4 -6
2017-03-31 -4 -4
2016-12-31 -3 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Entera Bio's earnings are expected to grow significantly at over 20% yearly.
  • Entera Bio's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:ENTX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Entera Bio Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ENTX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.48 1.48 1.48 1.00
2022-12-31 -0.38 -0.38 -0.38 1.00
2021-12-31 -0.69 -0.69 -0.69 1.00
2020-12-31 -0.56 -0.56 -0.56 1.00
2019-12-31 -0.58 -0.58 -0.58 1.00
NasdaqCM:ENTX Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.30
2018-09-30 -2.38
2018-06-30 -3.24
2018-03-31 -3.43
2017-12-31 -2.49
2017-09-30 -2.00
2017-06-30 -2.06
2017-03-31 -1.23
2016-12-31 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Entera Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Entera Bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Entera Bio has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ENTX Past Performance

  How has Entera Bio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Entera Bio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Entera Bio does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Entera Bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Entera Bio's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Entera Bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Entera Bio Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:ENTX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.50 -10.30 2.84 8.52
2018-09-30 -11.43 5.22 7.55
2018-06-30 -10.02 6.54 6.15
2018-03-31 -10.61 7.56 4.46
2017-12-31 -11.20 8.58 2.77
2017-09-30 -8.28 5.69 2.48
2017-06-30 -6.36 3.82 3.00
2017-03-31 -3.78 3.27 2.83
2016-12-31 -1.20 2.72 2.65
2015-12-31 -4.28 1.59 2.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Entera Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Entera Bio has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Entera Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Entera Bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Entera Bio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ENTX Health

 How is Entera Bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Entera Bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Entera Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Entera Bio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Entera Bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Entera Bio has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Entera Bio Company Filings, last reported 4 months ago.

NasdaqCM:ENTX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 10.12 0.00 11.52
2018-09-30 13.64 0.00 13.86
2018-06-30 -28.53 34.83 6.47
2018-03-31 -26.16 37.35 11.75
2017-12-31 -26.16 37.35 11.75
2017-09-30 -22.87 24.46 2.90
2017-06-30 -21.92 24.50 2.34
2017-03-31 -20.17 25.75 4.16
2016-12-31 -20.17 25.75 4.16
2015-12-31 -19.20 21.12 1.21
  • Entera Bio has no debt.
  • Entera Bio currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Entera Bio has sufficient cash runway for 1.2 years based on current free cash flow.
  • Entera Bio has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 42.6% each year.
X
Financial health checks
We assess Entera Bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Entera Bio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ENTX Dividends

 What is Entera Bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Entera Bio dividends.
If you bought $2,000 of Entera Bio shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Entera Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Entera Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:ENTX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:ENTX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Entera Bio has not reported any payouts.
  • Unable to verify if Entera Bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Entera Bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Entera Bio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Entera Bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Entera Bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Entera Bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ENTX Management

 What is the CEO of Entera Bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Phillip Schwartz
COMPENSATION $1,117,262
AGE 56
TENURE AS CEO 9.3 years
CEO Bio

Dr. Phillip Schwartz has been the Chief Executive Officer and Director at Entera Bio Ltd. since 2010. Prior to this, Dr. Schwartz served as the Scientific and Medical Development Manager for Endo Pharmaceuticals. Dr. Schwartz has over 10 years of experience in the pharmaceutical and biotech industries and served as a lecturer at Harvard Medical School.

CEO Compensation
  • Phillip's compensation has increased whilst company is loss making.
  • Phillip's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Entera Bio management team in years:

3.8
Average Tenure
56
Average Age
  • The tenure for the Entera Bio management team is about average.
Management Team

Phillip Schwartz

TITLE
CEO & Director
COMPENSATION
$1M
AGE
56
TENURE
9.3 yrs

Hillel Galitzer

TITLE
Chief Operating Officer
COMPENSATION
$514K
AGE
40
TENURE
5.3 yrs

Roger Garceau

TITLE
Chief Development Advisor & Director
COMPENSATION
$378K
AGE
64
TENURE
2.4 yrs

Arthur Santora

TITLE
Chief Medical Officer
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the Entera Bio board of directors in years:

2
Average Tenure
64
Average Age
  • The average tenure for the Entera Bio board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jerry Lieberman

TITLE
Chairman of the Board
COMPENSATION
$500K
AGE
71
TENURE
0.8 yrs

Phillip Schwartz

TITLE
CEO & Director
COMPENSATION
$1M
AGE
56
TENURE
9.3 yrs

Roger Garceau

TITLE
Chief Development Advisor & Director
COMPENSATION
$378K
AGE
64
TENURE
3.2 yrs

Faith Charles

TITLE
External Director
TENURE
0.7 yrs

Miranda Toledano

TITLE
External Director
AGE
41
TENURE
0.7 yrs

Zeev Bronfeld

TITLE
Director
AGE
67
TENURE
9.3 yrs

Yonatan Malca

TITLE
Director
AGE
52
TENURE
8.3 yrs

Jerry Ostrov

TITLE
Independent Director
AGE
69
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Entera Bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Entera Bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ENTX News

Simply Wall St News

ENTX Company Info

Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Entera Bio Ltd. operates as a subsidiary of D.N.A Biomedical Solutions Ltd.

Details
Name: Entera Bio Ltd.
ENTX
Exchange: NasdaqCM
Founded: 2010
$43,776,359
11,459,780
Website: http://www.enterabio.com
Address: Entera Bio Ltd.
Minrav Building,
Fifth Floor,
Jerusalem,
9112002,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ENTX Ordinary Shares Nasdaq Capital Market US USD 28. Jun 2018
Number of employees
Current staff
Staff numbers
19
Entera Bio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 06:44
End of day share price update: 2019/05/22 00:00
Last estimates confirmation: 2019/03/28
Last earnings filing: 2019/03/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.